In the announcement on 30/11/12 it was stated that 'The review start date will be advised to Tissue Therapies by the EMA.' This has yet to occur but I have not seen any announcements of cost cutting while shareholders wait for something to happen.
I have read posters views that it is not their fault which may or may not be the case. However they control the purse strings and I am yet to see an announcement stating that they are reining in costs. I would love to see some evidence of prudent financial management. Cutting costs during these times is a no brainer or is their idea of financial management a capital raising?
Cash available at October 2012 was $5,158,393. Wonder how much remains?
Add to My Watchlist
What is My Watchlist?